Documents

Double-digit revenue and profit growth, margin expansion, and strong chronic therapy momentum.

Strong growth, innovation, and strategic expansion drive value amid evolving risks and opportunities.

Strong FY26 growth, margin expansion, and robust outlook driven by chronic and specialty segments.

Chronic therapies and exports drove growth, with improved margins and positive outlook.

Q2 FY26 revenue up 21% year-on-year, but profit after tax down 21% on higher costs.

Q1 FY26 delivered robust revenue and EBITDA growth, but net profit fell on higher costs.

Q4 revenue up 27% YoY, margins improved, and VSC acquisition drives specialty growth.

Revenue up 24% YoY, margins improved, BSV integration and chronic segment drive growth.

Q2 FY25 revenue up 14% YoY, BSV acquisition boosts growth, margins, and specialty presence.

Q1 FY25 delivered double-digit revenue growth, margin resilience, and strategic expansion via BSV acquisition.